{"id":125775,"date":"2021-08-03T11:23:26","date_gmt":"2021-08-03T18:23:26","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/08\/capricor-therapeutics-exosome-based-vaccine-program"},"modified":"2021-08-03T11:23:26","modified_gmt":"2021-08-03T18:23:26","slug":"capricor-therapeutics-exosome-based-vaccine-program","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/08\/capricor-therapeutics-exosome-based-vaccine-program","title":{"rendered":"Capricor Therapeutics \u2013 Exosome-based vaccine program"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/capricor-therapeutics-exosome-based-vaccine-program.jpg\"><\/a><\/p>\n<p>Capricor on April 3 said it was continuing to develop its exosome platform technology as a potential COVID-19 vaccine, even as it pursued compassionate use approval for CAP-1002 (See above). The company seeks to develop two candidates. The first is a virus-like particle (VLP) similar in structure to an exosome, and produced by the same process developed by Capricor in its studies of CAP-1002. The other is an exosome-mRNA vaccine formulation designed to elicit a protective, long-lasting immune response to SARS-CoV-2 by targeting all four structural proteins of the virus.<\/p>\n<hr>\n<p>\n<strong>Candidates:<\/strong> Two vaccine candidates for the potential prevention of COVID-19.<\/p>\n<p><strong>Category: <\/strong><a href=\"https:\/\/www.genengnews.com\/category\/covid-19-candidates\/covid-19-vax\/\" target=\"_blank\" rel=\"noopener noreferrer\"> <strong>VAX<\/strong><\/a><\/p>\n<p><strong>Types:<\/strong> Vaccines based on exosomes derived from the company\u2019s proprietary cardiosphere-derived cells CDCs (CAP-2003) and engineered exosomes, both of which are in preclinical development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Capricor on April 3 said it was continuing to develop its exosome platform technology as a potential COVID-19 vaccine, even as it pursued compassionate use approval for CAP-1002 (See above). The company seeks to develop two candidates. The first is a virus-like particle (VLP) similar in structure to an exosome, and produced by the same [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-125775","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/125775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=125775"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/125775\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=125775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=125775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=125775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}